Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Ocugen Inc (OCGN)

Ocugen Inc (OCGN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 267,577
  • Shares Outstanding, K 291,320
  • Annual Sales, $ 6,040 K
  • Annual Income, $ -63,080 K
  • EBIT $ -56 M
  • EBITDA $ -55 M
  • 60-Month Beta 3.75
  • Price/Sales 42.16
  • Price/Cash Flow N/A
  • Price/Book 6.19
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.18
  • Most Recent Earnings $-0.05 on 11/14/24
  • Next Earnings Date 11/08/24
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Options Overview Details

View History
  • Implied Volatility 150.84% ( +21.58%)
  • Historical Volatility 72.79%
  • IV Percentile 58%
  • IV Rank 12.82%
  • IV High 663.01% on 11/27/23
  • IV Low 75.50% on 02/07/24
  • Put/Call Vol Ratio 0.04
  • Today's Volume 1,132
  • Volume Avg (30-Day) 2,329
  • Put/Call OI Ratio 0.08
  • Today's Open Interest 62,932
  • Open Int (30-Day) 65,340

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -0.05
  • Number of Estimates 2
  • High Estimate -0.05
  • Low Estimate -0.06
  • Prior Year -0.04
  • Growth Rate Est. (year over year) -25.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.8534 +5.57%
on 11/20/24
1.1300 -20.27%
on 11/08/24
-0.0375 (-4.00%)
since 10/21/24
3-Month
0.8534 +5.57%
on 11/20/24
1.4000 -35.65%
on 08/26/24
-0.3891 (-30.16%)
since 08/21/24
52-Week
0.3600 +150.25%
on 12/13/23
2.1050 -57.20%
on 03/25/24
+0.5139 (+132.79%)
since 11/21/23

Most Recent Stories

More News
Ocugen, Inc. Receives Orphan Medicinal Product Designation from EMA for OCU410ST in Treating ABCA4-Associated Retinopathies

Ocugen's OCU410ST receives orphan designation from EMA for treating rare retinal diseases, advancing towards clinical trials and potential market approval.Quiver AI SummaryOcugen, Inc. announced that the...

OCGN : 0.9009 (-1.92%)
Ocugen Announces European Medicines Agency Grants Orphan Medicinal Product Designation for Modifier Gene Therapy Candidate OCU410ST for Treatment of ABCA4-Associated Retinopathies including Stargardt Disease

OCGN : 0.9009 (-1.92%)
Ocugen, Inc. Reports Positive Preliminary Data from OCU410 Clinical Trial for Geographic Atrophy in Dry Age-Related Macular Degeneration

Ocugen announced positive early results for OCU410 in treating geographic atrophy, showing safety and efficacy.Quiver AI SummaryOcugen, Inc. announced promising preliminary results from the Phase 1 dose-escalation...

OCGN : 0.9009 (-1.92%)
Ocugen Announces Compelling Preliminary Data for OCU410—a Single Dose Novel Modifier Gene Therapy to Treat Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration

OCGN : 0.9009 (-1.92%)
Wall Street Expects These 2 Under-the-Radar Growth Stocks to Outperform

The recent quarterly results of these two growth stocks show that they have significant long-term growth potential.

MSFT : 412.87 (-0.63%)
META : 563.09 (-0.43%)
MNDY : 276.26 (+6.19%)
$SPX : 5,948.71 (+0.53%)
OCGN : 0.9009 (-1.92%)
Ocugen: Q3 Earnings Snapshot

Ocugen: Q3 Earnings Snapshot

OCGN : 0.9009 (-1.92%)
Ocugen (OCGN) Q3 2024 Earnings Call Transcript

OCGN earnings call for the period ending September 30, 2024.

OCGN : 0.9009 (-1.92%)
Ocugen Provides Business Update with Third Quarter 2024 Financial Results

OCGN : 0.9009 (-1.92%)
Ocugen Secures $30 Million in Debt Funding

OCGN : 0.9009 (-1.92%)
Ocugen Clinical Showcase Highlighting Progress in Retinal Gene Therapy Clinical Trials in New York City on Tuesday, November 12, 2024

OCGN : 0.9009 (-1.92%)

Business Summary

Ocugen Inc. is a clinical stage biopharmaceutical company. It is focused on discovering, developing and commercializing therapies which address rare and underserved eye diseases. The company's product pipeline consists of OCU400, OCU300, OCU100 and OCU200 which are in clinical stage. Ocugen Inc., formerly...

See More

Key Turning Points

3rd Resistance Point 0.9761
2nd Resistance Point 0.9571
1st Resistance Point 0.9290
Last Price 0.9009
1st Support Level 0.8819
2nd Support Level 0.8629
3rd Support Level 0.8348

See More

52-Week High 2.1050
Fibonacci 61.8% 1.4384
Fibonacci 50% 1.2325
Fibonacci 38.2% 1.0266
Last Price 0.9009
52-Week Low 0.3600

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar